Shanghai Fosun Pharmaceutical : COMPLETION OF DISCLOSEABLE TRANSACTION THE DISPOSAL OF PARTNERSHIP INTERESTS IN THE PARTNERSHIP AND EQUITY INTEREST IN THE GENERAL PARTNER AND SUBSCRIPTION OF NFC SHARES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

COMPLETION OF DISCLOSEABLE TRANSACTION

THE DISPOSAL OF PARTNERSHIP INTERESTS IN THE PARTNERSHIP AND

EQUITY INTEREST IN THE GENERAL PARTNER

AND

SUBSCRIPTION OF NFC SHARES

References are made to the Company's announcements dated 30 July, 1 August 2019 and 30 August 2019 (the ''Announcements''), the circular of the Company dated 3 September 2019 and the poll results announcement of the Company dated 21 October 2019, in connection with, among other things, the Proposed Disposal and Proposed Subscription. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Announcements.

COMPLETION OF THE PROPOSED DISPOSAL

The Board is pleased to announce that all conditions precedent under the Transaction Agreement have been satisfied and the Closing took place on 18 December 2019 (Eastern Standard Time, same as below) in accordance with the terms thereof. Upon the Closing, the Group ceased to hold any interests in the Partnership or shares in the General Partner directly.

- 1 -

COMPLETION OF THE PROPOSED SUBSCRIPTION

The Board is pleased to further announce that, NFC has allotted and issued 9,400,000 shares in NFC to Fosun Industrial in accordance with the terms and conditions of the Rollover Agreement, representing approximately 7.04% of the enlarged total number of issued shares of NFC as at 18 December 2019.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

19 December 2019

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang, Mr. Wang Can, Ms. Mu Haining and Mr. Liang Jianfeng; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

• for identification purposes only

- 2 -